Amedeo Smart

Free Medical Literature Service

 

Amedeo

HIV Infection
  Free Subscription

Articles published in
Lancet
    May 2026
  1. LAXMINARAYAN R, Limmathurotsakul D, de Abreu AL, Alimi Y, et al
    Meeting the 2024 UN General Assembly declaration targets on antimicrobial resistance.
    Lancet. 2026 May 19:S0140-6736(26)00979-7. doi: 10.1016/S0140-6736(26)00979.
    >> Share

  2. MENDELSON M, Brink A
    Emerging beta-lactam and beta-lactamase inhibitor strategies for complicated urinary tract infections.
    Lancet. 2026;407:1893-1895.
    >> Share

    April 2026
  3. SHANKAR-HARI M, Ming D, Mendelson M, Rupali P, et al
    The Lancet Commission on Sepsis: transforming sepsis care and outcomes.
    Lancet. 2026 Apr 22:S0140-6736(26)00648-3. doi: 10.1016/S0140-6736(26)00648.
    >> Share

  4. CHARANI E, Makamu T, Silal S, Laxminarayan R, et al
    Rethinking country classifications towards a more equitable global health future.
    Lancet. 2026 Apr 2:S0140-6736(26)00457-5. doi: 10.1016/S0140-6736(26)00457.
    >> Share

    March 2026
  5. PAN D, Choi JS, Choi MJ, Phillips R, et al
    Respiratory virus research needs its own PPIE.
    Lancet. 2026;407:1144-1145.
    >> Share

  6. KASUJJA FX, Aikaeli F, Garrib A, van Widenfelt E, et al
    Integrated community-based versus facility-based care for people with HIV, diabetes, and hypertension in sub-Saharan Africa (INTE-COMM): an open-label, multicountry, cluster-randomised trial.
    Lancet. 2026;407:1084-1094.
    >> Share

  7. WONG N, Barnes D, Hartley J, Yunger P, et al
    Time to change internal medicine training for UK resident doctors.
    Lancet. 2026 Mar 6:S0140-6736(26)00290-4. doi: 10.1016/S0140-6736(26)00290.
    >> Share

    February 2026
  8. ORKIN C, Ruane PJ, Hedgcock M, Gaultier C, et al
    Switch to single-tablet bictegravir-lenacapavir from a complex HIV regimen (ARTISTRY-1): a randomised, open-label, phase 3 clinical trial.
    Lancet. 2026 Feb 25:S0140-6736(26)00307-7. doi: 10.1016/S0140-6736(26)00307.
    >> Share

  9. RATEVOSIAN J, Beyrer C
    Fundamental PEPFAR reform risks a period of structural vulnerability in the HIV response.
    Lancet. 2026 Feb 24:S0140-6736(26)00369-7. doi: 10.1016/S0140-6736(26)00369.
    >> Share

  10. COLSON AE, Mills AM, Ramgopal MN, Bettacchi C, et al
    Switch to fixed-dose doravirine (100 mg) and islatravir (0.25 mg) once daily in virologically suppressed adults with HIV-1 on bictegravir, emtricitabine, and tenofovir alafenamide: 48-week results of a phase 3, multicentre, randomised, controlled, dou
    Lancet. 2026;407:611-621.
    >> Share

  11. ORKIN C, Mngqibisa R, Velez JD, Kumar P, et al
    Switch to fixed-dose doravirine (100 mg) and islatravir (0.25 mg) once daily in virologically suppressed adults with HIV-1 on oral antiretroviral therapy: 48-week results of a phase 3, multicentre, randomised, open-label, non-inferiority trial.
    Lancet. 2026;407:599-610.
    >> Share

  12. ESTRADA V, Cabello-Clotet N
    Beyond integrase: the rise of doravirine and islatravir in HIV management.
    Lancet. 2026;407:551-553.
    >> Share

    January 2026
  13. GRIFFIN DWJ, McMahon JH, Hoy JF
    A call for equity in organ transplantation for people with HIV.
    Lancet. 2026;407:222-223.
    >> Share

    December 2025
  14. MAJAHA M, Chikwari CD, Kizito S, Moyo D, et al
    HIV and alcohol misuse among miners in Zimbabwe.
    Lancet. 2025;404:2538.
    >> Share

  15. VAKANIAKI EH, Barhishindi I, Mubiala A, Malembaka EB, et al
    Maternal and neonatal outcomes after infection with monkeypox virus clade I during pregnancy in DR Congo: a pooled, prospective cohort study.
    Lancet. 2025 Dec 19:S0140-6736(25)02309-8. doi: 10.1016/S0140-6736(25)02309.
    >> Share

  16. GREEN A
    Botswana's HIV services struggle.
    Lancet. 2025 Dec 17:S0140-6736(25)02585-1. doi: 10.1016/S0140-6736(25)02585.
    >> Share

  17. LUCKEY A, Balasegaram M, Barbee LA, Batteiger TA, et al
    Zoliflodacin versus ceftriaxone plus azithromycin for treatment of uncomplicated urogenital gonorrhoea: an international, randomised, controlled, open-label, phase 3, non-inferiority clinical trial.
    Lancet. 2025 Dec 11:S0140-6736(25)01953-1. doi: 10.1016/S0140-6736(25)01953.
    >> Share

    November 2025
  18. THORNTON J
    Fiji faces major HIV outbreak.
    Lancet. 2025 Nov 30:S0140-6736(25)02430-4. doi: 10.1016/S0140-6736(25)02430.
    >> Share

  19. KARIM QA
    Lessons from Africa: health diplomacy in HIV prevention.
    Lancet. 2025 Nov 4:S0140-6736(25)01976-2. doi: 10.1016/S0140-6736(25)01976.
    >> Share

  20. MAYER KH, Beyrer C, Cohen MS, El-Sadr WM, et al
    Challenges and opportunities in developing integrated sexual and reproductive health programmes.
    Lancet. 2025;406:2168-2190.
    >> Share

  21. MEYER-RATH G, Jamieson L, Mudimu E, Snyman K, et al
    Who pays and what pays off in sexual and reproductive health? A review of the cost and cost-effectiveness of interventions and implications for future funding and markets.
    Lancet. 2025;406:2152-2167.
    >> Share

  22. PETERS RPH, Grinsztejn B, Celum C, Mayer KH, et al
    Innovations in the biomedical prevention, diagnosis, and service delivery of HIV and other sexually transmitted infections.
    Lancet. 2025;406:2133-2151.
    >> Share

  23. GRULICH AE, Mercer CH, Sturrock B, Baral S, et al
    Partial progress in sexual and reproductive health and rights: the influence of sociocultural, behavioural, structural, and technological changes on epidemiological trends.
    Lancet. 2025;406:2100-2118.
    >> Share

  24. NGEMA N
    A rights-based imperative for young women.
    Lancet. 2025;406:2038-2040.
    >> Share

    October 2025

  25. Global burden of 292 causes of death in 204 countries and territories and 660 subnational locations, 1990-2023: a systematic analysis for the Global Burden of Disease Study 2023.
    Lancet. 2025 Oct 12:S0140-6736(25)01917-8. doi: 10.1016/S0140-6736(25)01917.
    >> Share


  26. Global age-sex-specific all-cause mortality and life expectancy estimates for 204 countries and territories and 660 subnational locations, 1950-2023: a demographic analysis for the Global Burden of Disease Study 2023.
    Lancet. 2025 Oct 12:S0140-6736(25)01330-3. doi: 10.1016/S0140-6736(25)01330.
    >> Share


  27. Burden of 375 diseases and injuries, risk-attributable burden of 88 risk factors, and healthy life expectancy in 204 countries and territories, including 660 subnational locations, 1990-2023: a systematic analysis for the Global Burden of Disease Stud
    Lancet. 2025 Oct 12:S0140-6736(25)01637-X. doi: 10.1016/S0140-6736(25)01637.
    >> Share

  28. BEKKER LG, Joseph Davey D, Saidi F
    Two for two: lenacapavir during pregnancy and lactation.
    Lancet. 2025;406:1560-1561.
    >> Share

    September 2025

  29. The global, regional, and national burden of cancer, 1990-2023, with forecasts to 2050: a systematic analysis for the Global Burden of Disease Study 2023.
    Lancet. 2025 Sep 24:S0140-6736(25)01635-6. doi: 10.1016/S0140-6736(25)01635.
    >> Share

    July 2025
  30. BATHEJA D, Saint V, Dobreva Z, Goel S, et al
    Integrating gender and equity commitments in the revised global action plan on antimicrobial resistance.
    Lancet. 2025 Jul 16:S0140-6736(25)01377-7. doi: 10.1016/S0140-6736(25)01377.
    >> Share


  31. Global HIV targets: a roadmap to 2030 and beyond.
    Lancet. 2025 Jul 16:S0140-6736(25)01449-7. doi: 10.1016/S0140-6736(25)01449.
    >> Share

  32. DUGDALE CM, Ufio O, Giardina J, Shebl F, et al
    Estimating the effect of maternal viral load on perinatal and postnatal HIV transmission: a systematic review and meta-analysis.
    Lancet. 2025 Jul 10:S0140-6736(25)00765-2. doi: 10.1016/S0140-6736(25)00765.
    >> Share

  33. JOHN-STEWART G, Njuguna I
    Getting to zero: when can we guarantee vertical transmission of HIV will not occur?
    Lancet. 2025 Jul 10:S0140-6736(25)01282-6. doi: 10.1016/S0140-6736(25)01282.
    >> Share

  34. LAZARUS JV, Bansal MB, Kanwal F, Lofton H, et al
    Reflections on the Lancet Commission on Investing in Health's Global Health 2050 report.
    Lancet. 2025;406:30-31.
    >> Share

  35. HALLETT TB, Menzies NA, Resch S, Pretorius C, et al
    The case for optimal investment in combating HIV, tuberculosis, and malaria: a global modelling study.
    Lancet. 2025 Jul 3:S0140-6736(25)00831-1. doi: 10.1016/S0140-6736(25)00831.
    >> Share

    June 2025
  36. CAVALCANTI DM, de Oliveira Ferreira de Sales L, da Silva AF, Basterra EL, et al
    Evaluating the impact of two decades of USAID interventions and projecting the effects of defunding on mortality up to 2030: a retrospective impact evaluation and forecasting analysis.
    Lancet. 2025 Jun 30:S0140-6736(25)01186-9. doi: 10.1016/S0140-6736(25)01186.
    >> Share

  37. RAO S, Samalin-Scalzi E, Evesque L, Ben Abdelghani M, et al
    Retifanlimab with carboplatin and paclitaxel for locally recurrent or metastatic squamous cell carcinoma of the anal canal (POD1UM-303/InterAACT-2): a global, phase 3 randomised controlled trial.
    Lancet. 2025;405:2144-2152.
    >> Share

  38. BOZICEVIC I, Oreskovic S, van der Graaf R, McKee M, et al
    Open letter in support of WHO.
    Lancet. 2025 Jun 13:S0140-6736(25)01174-2. doi: 10.1016/S0140-6736(25)01174.
    >> Share

    May 2025
  39. SHIU C, Ho J, Aung MN, Chen WT, et al
    From disappointment to despair: USAID cuts to Myanmar's HIV services.
    Lancet. 2025 May 1:S0140-6736(25)00714-7. doi: 10.1016/S0140-6736(25)00714.
    >> Share

    April 2025
  40. ROSA WE, Connor S, Aggarwal G, Alsirafy S, et al
    Relieve the suffering: palliative care for the next decade.
    Lancet. 2025 Apr 18:S0140-6736(25)00678-6. doi: 10.1016/S0140-6736(25)00678.
    >> Share

  41. UNEMO M, Wi T
    Gepotidacin shows promise for the treatment of uncomplicated gonorrhoea.
    Lancet. 2025 Apr 11:S0140-6736(25)00680-4. doi: 10.1016/S0140-6736(25)00680.
    >> Share

  42. ROSS JDC, Wilson J, Workowski KA, Taylor SN, et al
    Oral gepotidacin for the treatment of uncomplicated urogenital gonorrhoea (EAGLE-1): a phase 3 randomised, open-label, non-inferiority, multicentre study.
    Lancet. 2025 Apr 11:S0140-6736(25)00628-2. doi: 10.1016/S0140-6736(25)00628.
    >> Share

  43. NDEMBI N, Karuna S, Cowden J, Cagigi A, et al
    Accelerating vaccine development in Africa: lessons from HIV research.
    Lancet. 2025 Apr 10:S0140-6736(25)00564-1. doi: 10.1016/S0140-6736(25)00564.
    >> Share

  44. SIDIBE M, Makgoba TC, Paul B, Brilliant B, et al
    Accelerating domestic investments to end AIDS in Africa.
    Lancet. 2025 Apr 8:S0140-6736(25)00685-3. doi: 10.1016/S0140-6736(25)00685.
    >> Share

  45. CLUVER L, Makangila G, Hillis S, Ntwali-N'Konzi JP, et al
    Protecting Africa's children from extreme risk: a runway of sustainability for PEPFAR programmes.
    Lancet. 2025 Apr 8:S0140-6736(25)00401-5. doi: 10.1016/S0140-6736(25)00401.
    >> Share

  46. OKANO JT, Blower S
    Long-acting HIV preventive treatments for remote rural communities.
    Lancet. 2025;405:1143.
    >> Share

    March 2025
  47. AL ZAMEL AM, Saeed AA, Elmubarak M
    Sudan's war and the burden of HIV: a call for urgent intervention.
    Lancet. 2025 Mar 27:S0140-6736(25)00547-1. doi: 10.1016/S0140-6736(25)00547.
    >> Share

  48. PRASAD A
    Rachael Burke: integrating equitable HIV and TB research and care.
    Lancet. 2025 Mar 17:S0140-6736(25)00515-X. doi: 10.1016/S0140-6736(25)00515.
    >> Share

  49. PRASAD A
    Aliasgar Esmail: innovation in TB and HIV research and medicine.
    Lancet. 2025 Mar 17:S0140-6736(25)00514-8. doi: 10.1016/S0140-6736(25)00514.
    >> Share

  50. JOGIRAJU V, Pawar P, Yager J, Ling J, et al
    Pharmacokinetics and safety of once-yearly lenacapavir: a phase 1, open-label study.
    Lancet. 2025 Mar 10:S0140-6736(25)00405-2. doi: 10.1016/S0140-6736(25)00405.
    >> Share

  51. RYOM L
    The potential for annual long-acting HIV pre-exposure prophylaxis.
    Lancet. 2025 Mar 10:S0140-6736(25)00452-0. doi: 10.1016/S0140-6736(25)00452.
    >> Share

  52. BARMANIA S
    Research focus: Institute of HIV Research and Innovation.
    Lancet. 2025;405:771.
    >> Share

  53. TRAJMAN A, Campbell JR, Kunor T, Ruslami R, et al
    Tuberculosis.
    Lancet. 2025;405:850-866.
    >> Share

    February 2025
  54. DEVI S
    A new era for HIV in the Philippines?
    Lancet. 2025;405:611-612.
    >> Share

  55. HOLT E
    Ukraine HIV services severely curtailed by US aid freeze.
    Lancet. 2025;405:455.
    >> Share

  56. RATEVOSIAN J, Millett G, Honermann B, Bennett S, et al
    PEPFAR under review: what's at stake for PEPFAR's future.
    Lancet. 2025 Feb 7:S0140-6736(25)00258-2. doi: 10.1016/S0140-6736(25)00258.
    >> Share

    January 2025
  57. BROSIUS I, Vakaniaki EH, Mukari G, Munganga P, et al
    Epidemiological and clinical features of mpox during the clade Ib outbreak in South Kivu, Democratic Republic of the Congo: a prospective cohort study.
    Lancet. 2025 Jan 29:S0140-6736(25)00047-9. doi: 10.1016/S0140-6736(25)00047.
    >> Share

  58. KAMAL-YANNI M, Gangte L, Kittitrakul C, Meyer S, et al
    Is MSF changing course on access to medicines?
    Lancet. 2025;405:124-125.
    >> Share

    November 2024
  59. THE LANCET
    Triumphs and threats: HIV in 2024.
    Lancet. 2024;404:2131.
    >> Share

  60. BENDER IGNACIO RA, Shapiro AE, Montano MA, Titanji BK, et al
    An urgent call to address the intersection of mpox and HIV in Africa.
    Lancet. 2024 Nov 28:S0140-6736(24)02542-X. doi: 10.1016/S0140-6736(24)02542.
    >> Share

  61. NORHEIM OF, Chang AY, Bolongaita S, Barraza-Llorens M, et al
    Halving premature death and improving quality of life at all ages: cross-country analyses of past trends and future directions.
    Lancet. 2024 Nov 20:S0140-6736(24)02417-6. doi: 10.1016/S0140-6736(24)02417.
    >> Share

  62. COUSINS S
    New HIV drugs: access debates.
    Lancet. 2024;404:1797-1798.
    >> Share

    September 2024
  63. SALEH E, Dousa KM, Babiker A, Rahma NEAA, et al
    Health and humanitarian toll of Sudan's forgotten war.
    Lancet. 2024 Sep 24:S0140-6736(24)01939-1. doi: 10.1016/S0140-6736(24)01939.
    >> Share

    August 2024
  64. KIZITO S, Nabayinda J, Nabunya P, Ssewamala FM, et al
    HIV and tuberculosis in Uganda: are we neglecting poverty?
    Lancet. 2024;404:844-845.
    >> Share

  65. BASSEY AE
    The health of migrants at the intersection of mpox and HIV.
    Lancet. 2024 Aug 23:S0140-6736(24)01753-7. doi: 10.1016/S0140-6736(24)01753.
    >> Share

  66. MODY A, Sohn AH, Iwuji C, Tan RKJ, et al
    The battle against paediatric HIV is far from over - Authors' reply.
    Lancet. 2024;404:522-523.
    >> Share

  67. VAN DE PERRE P, Tylleskar T
    The battle against paediatric HIV is far from over.
    Lancet. 2024;404:522.
    >> Share

  68. NABAYINDA J, Kizito S, Nagawa A, Ssewamala FM, et al
    Reducing HIV in young women in Uganda: the need for autonomy.
    Lancet. 2024;404:519-520.
    >> Share

  69. SALEEM SM, Haq Z
    Bridging gaps in vertical transmission of HIV, syphilis, and hepatitis B in India.
    Lancet. 2024;404:428-429.
    >> Share

    July 2024
  70. KIRBY T
    Beatriz Grinsztejn: leading Brazil's response to HIV.
    Lancet. 2024;404:233.
    >> Share

    May 2024
  71. JAFFAR S
    Integrated HIV, diabetes, and hypertension care in sub-Saharan Africa - Authors' reply.
    Lancet. 2024;403:2292.
    >> Share

  72. CAI S, Xu Z, Zhao Y, Zuhlke L, et al
    Integrated HIV, diabetes, and hypertension care in sub-Saharan Africa.
    Lancet. 2024;403:2291.
    >> Share

  73. HAVLIR D, Kamya MR, Petersen M
    Integrated HIV, diabetes, and hypertension care in sub-Saharan Africa.
    Lancet. 2024;403:2291-2292.
    >> Share

  74. MAERTENS GN, Purcell DFJ, Rosadas C, Bradshaw D, et al
    Why not eliminate HTLV-1 while eliminating HIV-1?
    Lancet. 2024;403:2288-2289.
    >> Share


  75. The HIV response beyond 2030: preparing for decades of sustained HIV epidemic control in eastern and southern Africa.
    Lancet. 2024 May 20:S0140-6736(24)00980-2. doi: 10.1016/S0140-6736(24)00980.
    >> Share

  76. LEWNARD JA, Charani E, Gleason A, Hsu LY, et al
    Burden of bacterial antimicrobial resistance in low-income and middle-income countries avertible by existing interventions: an evidence review and modelling analysis.
    Lancet. 2024 May 20:S0140-6736(24)00862-6. doi: 10.1016/S0140-6736(24)00862.
    >> Share

  77. MENDELSON M, Lewnard JA, Sharland M, Cook A, et al
    Ensuring progress on sustainable access to effective antibiotics at the 2024 UN General Assembly: a target-based approach.
    Lancet. 2024 May 20:S0140-6736(24)01019-5. doi: 10.1016/S0140-6736(24)01019.
    >> Share

    April 2024
  78. TUTLAM NT, Kizito S, Liyew TW, Ssewamala FM, et al
    HIV among refugee youth in Uganda: unmasking the crisis.
    Lancet. 2024;403:1536-1537.
    >> Share


  79. Global incidence, prevalence, years lived with disability (YLDs), disability-adjusted life-years (DALYs), and healthy life expectancy (HALE) for 371 diseases and injuries in 204 countries and territories and 811 subnational locations, 1990-2021: a sys
    Lancet. 2024 Apr 15:S0140-6736(24)00757-8. doi: 10.1016/S0140-6736(24)00757.
    >> Share


  80. Global burden of 288 causes of death and life expectancy decomposition in 204 countries and territories and 811 subnational locations, 1990-2021: a systematic analysis for the Global Burden of Disease Study 2021.
    Lancet. 2024 Apr 3:S0140-6736(24)00367-2. doi: 10.1016/S0140-6736(24)00367.
    >> Share

    March 2024
  81. BEYRER C, Kamarulzaman A, Isbell M, Amon J, et al
    Under threat: the International AIDS Society-Lancet Commission on Health and Human Rights.
    Lancet. 2024 Mar 20:S0140-6736(24)00302-7. doi: 10.1016/S0140-6736(24)00302.
    >> Share

  82. WATTS G
    Andrew Kerkhoff: award-winning TB and HIV physician-scientist.
    Lancet. 2024 Mar 15:S0140-6736(24)00539-7. doi: 10.1016/S0140-6736(24)00539.
    >> Share

  83. KANKASA C, Mennecier A, Sakana BLD, Moles JP, et al
    Optimised prevention of postnatal HIV transmission in Zambia and Burkina Faso (PROMISE-EPI): a phase 3, open-label, randomised controlled trial.
    Lancet. 2024 Mar 11:S0140-6736(23)02464-9. doi: 10.1016/S0140-6736(23)02464.
    >> Share

  84. MUTALE W, Herce ME
    Closing the gap in paediatric HIV infections: how available tools and technology can accelerate progress towards ending AIDS by 2030.
    Lancet. 2024 Mar 11:S0140-6736(24)00366-0. doi: 10.1016/S0140-6736(24)00366.
    >> Share


  85. Global age-sex-specific mortality, life expectancy, and population estimates in 204 countries and territories and 811 subnational locations, 1950-2021, and the impact of the COVID-19 pandemic: a comprehensive demographic analysis for the Global Burden
    Lancet. 2024 Mar 8:S0140-6736(24)00476-8. doi: 10.1016/S0140-6736(24)00476.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016